Pharmacotherapy for prehypertension - Mission accomplished?

New England Journal of Medicine

Volumn 354, Issue 16, 2006, Pages 1742-1744

  Schunkert, Heribert ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ALCOHOL CONSUMPTION; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DEMOGRAPHY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG CLEARANCE; EDITORIAL; HUMAN; HYPERTENSION; LIFE EXPECTANCY; LIFESTYLE; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE; TARGET ORGAN; WEIGHT REDUCTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; HUMANS; HYPERTENSION; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 33645869247     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe068057     Document Type: Editorial

References (12)

1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72. [Erratum, JAMA 2003;290:197.]
2. Qureshi AI, Suri MF, Kirmani JF, Divani AA. Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000. Med Sci Monit 2005;11:CR403-CR409.
3. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001;345:1291-7.
4. Franco OH, Peeters A, Bonneux L, de Laet C. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: life course analysis. Hypertension 2005;46:280-6.
5. Russell LB, Valiyeva E, Carson JL. Effects of prehypertension on admissions and deaths: a simulation. Arch Intern Med 2004;164:2119-24. [Erratum, Arch Intern Med 2005;165:1720.]
6. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006;354:1685-97.
7. Harrap SB, Van der Merwe WM, Griffin SA, Macpherson F, Lever AF. Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term. Hypertension 1990;16:603-14.
8. Liszka HA, Mainous AG III, King DE, Everett CJ, Egan BM. Prehypertension and cardiovascular morbidity. Ann Fam Med 2005;3:294-9.
9. Kshirsagar AV, Carpenter M, Bang H, Wyatt SB, Colindres RE. Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. Am J Med 2006;119:133-41.
10. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217-25.
11. Svetkey LP. Management of prehypertension. Hypertension 2005;45:1056-61.
12. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.